Loading stock data…
FULC
$3.52+0.08 (+2.33%)
After Hours$3.55+0.03 (+0.85%)· Last close Jun 9
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Fulcrum Therapeutics, Inc. in the Healthcare sector is trading at $3.52. Wall Street consensus targets $6.62 (8 analysts), implying a +88.2% move over the next 12 months. The stock is currently near its 52-week low of $2.83, remaining 59.5% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 29 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +88.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 29) — potential for technical mean-reversion
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$3.52
Potential Downside
0%
Whystock Fair Value$3.52
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus8 analysts
Hold
Mean target$6.63+88.2%
Range$3.00 – $18.00
Fundamentals
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage produ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-22.84%
Volume
Today's trading volume
3.95M
Recent News
A Look At Fulcrum Therapeutics (FULC) Valuation After Scrapping Lead Sickle Cell Drug And Restructuring
Why Fulcrum Therapeutics Stock Is Back in Focus Fulcrum Therapeutics (FULC) is back on investors' radar after the company scrapped development of its lead sickle cell disease drug, pociredir, and moved quickly into a deep restructuring and review of options. See our latest analysis for Fulcrum Therapeutics. The discontinuation of pociredir and the sweeping restructuring have driven sharp volatility. The stock is down about 52% on a 1 year total shareholder return basis. The 3 year total...
Fulcrum Therapeutics (FULC) Loses 51% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Fulcrum Therapeutics (FULC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
FULC Stock Crashes as Cancer Risk Forces Its Only Drug Program's End
Fulcrum Therapeutics stock sinks 51% after ending pociredir development in SCD due to FDA cancer-risk concerns, leaving no clinical-stage assets.
Why Did FULC, MVIS, HRTX Stocks Plunge To 52-Week Lows Today?
The selloff highlighted the risks facing smaller companies operating in biotechnology and emerging technology.
This Biotech Stock Plunges 54%. Its Sickle Cell Drug Has ‘No Viable Path Forward.’
Fulcrum Therapeutics discontinues its pociredir program after the Food and Drug Administration raises concerns.